The Mayo Clinic Cancer Center (MCCC) is poised to continue to provide an outstanding training experience for academic oncologists and translational cancer researchers. This institution remains at the epicenter of high-quality, practice-changing cancer clinical/translational trials. The MCCC is a National Cancer Institute (NCI)-designated comprehensive cancer center and is in its 36th year of continuous funding. Its funding portfolio includes an NCI-funded Phase I grant;a Phase II contract;7 SPORE's (prostate, pancreas, breast, brain, ovary, multiple myeloma, and lymphoma);and multiple investigator-initiated grants. It maintains strong ties to national cancer cooperative groups, including the North Central Cancer Treatment Group, for which the Mayo Clinic is the sole research base, and the American College of Surgeons Cooperative Group. The Mayo Graduate School of Medicine is one of the largest training programs in the world, educating 1400+ physicians annually in over 100 specialties. Thus, the MCCC seeks to renew the "Paul Calabresi Program in Clinical and Translational Research at the Mayo Clinic," requesting 7 positions/year. The MCCC has been privileged to hold this award since 2001. To date, all 21 scholars hold academic appointments, 67% have secured other funding, some hold leadership positions in academic oncology, and each has published in cancer therapeutics, cumulatively amassing 700+ publications. In this application, as before, scholars must focus on 1 of 6 research tracks that align with MCCC Programs: Gastrointestinal Malignancies, Genitourinary Malignancies, Hematology, Neuro-oncology, Novel Therapeutics, or Women's Cancers. Multidisciplinary teams will work with each scholar as he/she completes coursework, embarks upon hands-on research, and strives for career independence. Co-principal investigators, Aminah Jatoi, M.D., who is Associate Director for Education and Training for the MCCC, and Lynn Hartmann, M.D., who has overseen this program since its inception, will together lead this training program. An Advisory Committee comprised of 7 MCCC leaders will provide oversight. The MCCC seeks to train the next generation of investigators to enable them to conduct cutting- edge, hypothesis-driven research in cancer therapeutics.

Public Health Relevance

The Mayo Clinic Cancer Center (MCCC) is a National Cancer Institute (NCI)-designated comprehensive cancer center and is in its 36th year of continuous funding. It remains at the epicenter of high-quality, practice-changing cancer clinical/translational trials. The MCCC now seeks to renew the Paul Calabresi Program in Clinical and Translational Research at the Mayo Clinic in order to train the next generation of investigators who will conduct cutting-edge, hypothesis-driven research in cancer therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA090628-13
Application #
8504970
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (J1))
Program Officer
Damico, Mark W
Project Start
2001-09-25
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$897,597
Indirect Cost
$84,000
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Egan, Jan B; Barrett, Michael T; Champion, Mia D et al. (2014) Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements. PLoS One 9:e87113
Kumar, S K; Dispenzieri, A; Lacy, M Q et al. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122-8
Ramakrishnan, V; Painuly, U; Kimlinger, T et al. (2014) Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia 28:1519-28
Kumar, S K; Mikhael, J; Laplant, B et al. (2014) Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplant 49:201-5
Yoon, Harry H; Sukov, William R; Shi, Qian et al. (2014) HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer 120:415-24
Opyrchal, Mateusz; Salisbury, Jeffrey L; Zhang, Shuya et al. (2014) Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ER? expression in initially ER?+ breast cancer cells. PLoS One 9:e96995
Gonsalves, W I; Rajkumar, S V; Gupta, V et al. (2014) Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia 28:2060-5
Cunningham, J M; Cicek, M S; Larson, N B et al. (2014) Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 4:4026
Bi, Yan; Mukhopadhyay, Dhriti; Drinane, Mary et al. (2014) Endocytosis of collagen by hepatic stellate cells regulates extracellular matrix dynamics. Am J Physiol Cell Physiol 307:C622-33
Boughey, Judy C; Hoskin, Tanya L; Cheville, Andrea L et al. (2014) Risk factors associated with breast lymphedema. Ann Surg Oncol 21:1202-8

Showing the most recent 10 out of 137 publications